Followers | 4053 |
Posts | 151256 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Wednesday, November 29, 2023 1:13:18 PM
5/4/2023, 8:05:01 AMApril amended note fully converted.
Did you find this tip useful?YesNo
4/13/2023, 9:10:54 AMOn April 13, 2023, the Company and FiveT IM entered into an amendment to the FiveT Loan (the “FiveT Loan Amendment”), which (i) amends to the conversion price of the FiveT Loan to a fixed price equal to the lower of (a) the mean daily trading volume weighted average price (“VWAP”) of the Company’s common shares, par value CHF 0.20 per share, on the Nasdaq Stock Market on the 20 trading days preceding the effective date of the FiveT Loan Amendment or (b) 90% of the VWAP on the effective date of the FiveT Loan Amendment
Did you find this tip useful?YesNo
Show 1 more entry
https://dilutiontracker.com/app/search/CYTO?a=dbb88c
Recent CYTO News
- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation • GlobeNewswire Inc. • 05/01/2024 12:47:00 PM
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal • GlobeNewswire Inc. • 04/24/2024 12:47:00 PM
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 • GlobeNewswire Inc. • 04/04/2024 12:45:00 PM
- Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines • GlobeNewswire Inc. • 03/25/2024 12:47:00 PM
- Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal • GlobeNewswire Inc. • 02/07/2024 01:47:00 PM
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment • GlobeNewswire Inc. • 01/24/2024 01:47:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 01/22/2024 10:02:55 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/22/2024 05:15:31 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:45:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:40:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 09:30:47 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 01/08/2024 10:02:56 PM
- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit • GlobeNewswire Inc. • 01/08/2024 01:47:00 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 12/29/2023 01:47:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:01:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 01:00:31 PM
- Altamira Therapeutics Provides Investor and Business Update • GlobeNewswire Inc. • 12/11/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/08/2023 02:00:02 PM
- Altamira Therapeutics to Host Investor & Business Update Call on December 11th • GlobeNewswire Inc. • 12/05/2023 05:54:05 PM
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 11/29/2023 03:20:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/22/2023 09:30:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 01:00:23 PM
- Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business • GlobeNewswire Inc. • 11/17/2023 02:04:00 PM
- Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine • GlobeNewswire Inc. • 11/10/2023 01:47:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM